Side-by-side · Research reference

CrystagenvsMT-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BFDA-ApprovedHUMAN-REVIEWED9/51 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

MT-1

α-MSH Analogue · FDA-Approved

16 mgImplant dose

13 AAPeptide lengthChawathe 2026

2019FDA approval

SQ Implant · 60-Day Release

01Mechanism of Action

Parameter

Crystagen

MT-1

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026

Antibody development

—

02Dosage Protocols

Parameter

Crystagen

MT-1

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

16 mg subcutaneous implant

FDA-approved formulation (Scenesse).

Evidence basis

Animal / mechanistic

Phase 3 RCT / FDA-approved orphan drug

Route

Subcutaneous (presumed from bioregulator class)

Subcutaneous implant — upper arm or abdomen

Frequency

Unknown — bioregulator protocols variable

Every 60 days

Sustained release implant — no daily administration required.

Duration

Unknown — chronic administration presumed in animal models

Seasonal use (spring–autumn typical)

Aligned with peak UV exposure months.

Half-life

Not reported

—

Indication

—

Erythropoietic protoporphyria (EPP)

Narrow FDA approval — not licensed for cosmetic tanning.

Stability

—

Norleucine/D-Phe substitutions enhance peptidase resistance

Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).

04Side Effects & Safety

Parameter

Crystagen

MT-1

Published adverse events

None reported in available animal literature

—

Human safety data

Absent — no controlled human trials identified

—

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

Nausea

—

Common (>10%) — mild, transient

Implant site reaction

—

Erythema, bruising, tenderness at insertion site

Hyperpigmentation

—

Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010 Habbema 2017

Expected melanogenic response — complicates pigmented lesion surveillance.

Melanocytic changes

—

Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017

Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.

Headache

—

Occasional (MC1R-independent melanocortin effects)

Photosensitivity (paradoxical)

—

Rare phototoxic reactions despite melanin increase

Contamination risk (unregulated)

—

Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010 Habbema 2017

Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

MT-1

·Hypersensitivity to afamelanotide or excipients
·Hepatic impairment (no safety data)
·Renal impairment (no safety data)

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

MT-1

·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
·Pregnancy/lactation (insufficient data)
·Photosensitive dermatoses (other than EPP)

05Administration Protocol

Parameter

Crystagen

MT-1

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.

5. Monitoring

—

Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

MT-1

— no documented stacks